Clinical Trials Logo

Severe Hemophilia A clinical trials

View clinical trials related to Severe Hemophilia A.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06142552 Recruiting - Severe Hemophilia A Clinical Trials

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Start date: December 27, 2023
Phase: Phase 3
Study type: Interventional

To evaluate the prophylactic efficacy of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in patients with severe hemophilia A. To evaluate the safety of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in patients with severe hemophilia A. Secondary purpose: To evaluate the efficacy of recombinant human coagulation factor Ⅷ-Fc fusion protein for injection (FRSW117) in hemostasis and surgical hemostasis in patients with severe hemophilia A. To evaluate the pharmacokinetic (PK) characteristics of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in treated patients with severe hemophilia A. To evaluate the immunogenicity of recombinant human coagulation factor Ⅷ-Fc fusion protein (FRSW117) for injection in treated patients with severe hemophilia A.

NCT ID: NCT05935358 Recruiting - Severe Hemophilia A Clinical Trials

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

NuPOWER
Start date: February 2024
Phase: Phase 4
Study type: Interventional

Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis

NCT ID: NCT05802836 Recruiting - Severe Hemophilia A Clinical Trials

Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

NAVIGATE
Start date: April 26, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.